Fresh From the Bench: Latest Federal Circuit Court Case
Contributed by Schwabe Williamson & Wyatt. Originally published on Patexia; republished here as part of the LexDana archive.
CASE OF THE WEEK
Polaris Innovations Ltd. v. Brent, Appeal No. 2019-1483 (Fed. Cir. Sept. 15, 2022)
In our Case of the Week, the Federal Circuit provided what appears to be its first precedential opinion construing Section 317 of the Patent Act—a provision concerning the effect of settlement during an America Invents Act (AIA) proceeding. The Court’s opinion construes the statute in ways that may be unexpected for parties who seek to settle inter partes review (IPR) petitions.
Polaris sued NVIDIA Corporation for infringement of two patents. NVIDIA filed two IPRs, which matured to a final written decision of invalidity. Polaris appealed. The parties then settled, and NVIDIA withdrew from the appeals. The Patent Trial and Appeal Board (PTAB) intervened to defend its decisions in the IPRs.
Read more.
By Nika Aldrich
ALSO THIS WEEK
SawStop Holding LLC v. Vidal, Appeals Nos. 2021-1537, -2105 (Fed. Cir. Sept. 14, 2022)
The Federal Circuit affirmed the district court’s grant of summary judgment in favor of the Patent and Trademark Office (PTO) decision to deny patent term adjustments to SawStop. The decision rests on the interpretation of 35 U.S.C. § 154(b)(1)(C), which authorizes extensions when delays are the result of appellate review, specifically when “the patent was [1] issued under a decision in the review [2] reversing an adverse determination of patentability.” SawStop had appealed to the PTAB regarding claims for two patents: “the ’476 patent” and “the ’796 patent.” Regarding the ’476 patent, the Federal Circuit held that a patent term extension could not be granted because SawStop’s appeal to the PTAB “resulted in no substantive change in the patentability” of the relevant claim (both the PTO and the PTAB had rejected the claim, but on different grounds). Regarding the ’796 patent, the Federal Circuit held that a patent term extension did not apply because the statute requiring a patent be “issued under a decision in review” means “that at least one claim must ‘issue[] under’ the mandate of the appellate decision.” In the ’796 patent, the claim appealed to the district court did not issue in the patent.
The opinion can be found here.
By Megan Needham
Edited by Nika Aldrich and Scott D. Eads, Schwabe, Williamson & Wyatt
More insights
Federal Circuit Affirms Invalidation of Patent for Lack of Enablement of Claims Directed to a Method of Treating a Patient with a Unit Dosage in Wyeth Llc v Astrazeneca Pharmaceuticals Lp
Written by : Eric Furman, Ph.D. and Ashley C. Morales Key Takeaway: Federal Circuit invalidates patent claims directed to a method for treating non-small cell lung cancer through administration of “a unit dosage” of an irreversible epidermal…
When About Becomes Indefinite Federal Circuit Provides Guidance for Life Science Patent Applications Regarding Limits of Approximation in Enviro Tech v Safe Foods
Written by : Jason J. Jardine and Kenneth O. Aruda, Ph.D. Key Takeaway: The term “about” remains useful in biotech and pharmaceutical claims, but only if the patent provides objective guidance about what the term means. Absent that guidance,…
When Any Patent Means No Patent Federal Circuit Reverses Non Specific Verdict
Written by : Brian C. Barnes and Sophia F. Zahn OLLNOVA TECHNOLOGIES LTD. v. ECOBEE TECHNOLOGIES ULC [OPINION] Before Chen , Cunningham, and Stark. Appeal from the United States District Court for the Eastern District of Texas. Summary : A verdict form…